Evidence map›Paper›PMID 42490870›Full record

ArticleFrontiers in digital health2026

Identifying risk factors for drug use recurrence with ecological momentary assessment, wearable technologies, and machine learning: a feasibility trial of peer recovery support specialist intervention.

James J Mahoney Iii, Victor S Finomore, Jennifer L Marton, Lucinda J England, Sara McFoy, Danielle Romanoff, Jad Ramadan, Anahita Zarei, Amer Mahyoub, Jessie Crooks and 4 more

Abstract read
In one paragraph

Article in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

James J Mahoney IiiDepartment of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville, VA, United States.
Victor S FinomoreDepartment of Neuroscience, Rockefeller Neuroscience Institute, West Virginia University School of Medicine, Morgantown, WV, United States.
Jennifer L MartonDepartment of Neuroscience, Rockefeller Neuroscience Institute, West Virginia University School of Medicine, Morgantown, WV, United States.
Lucinda J EnglandDepartment of Behavioral Medicine and Psychiatry, Rockefeller Neuroscience Institute, West Virginia University School of Medicine, Morgantown, WV, United States.
Sara McFoyDepartment of Neuroscience, Rockefeller Neuroscience Institute, West Virginia University School of Medicine, Morgantown, WV, United States.
Danielle RomanoffDepartment of Neuroscience, Rockefeller Neuroscience Institute, West Virginia University School of Medicine, Morgantown, WV, United States.
Jad RamadanDepartment of Neuroscience, Rockefeller Neuroscience Institute, West Virginia University School of Medicine, Morgantown, WV, United States.
Anahita ZareiDepartment of Neuroscience, Rockefeller Neuroscience Institute, West Virginia University School of Medicine, Morgantown, WV, United States.
Amer MahyoubDepartment of Neuroscience, Rockefeller Neuroscience Institute, West Virginia University School of Medicine, Morgantown, WV, United States.
Jessie CrooksDepartment of Behavioral Medicine and Psychiatry, Rockefeller Neuroscience Institute, West Virginia University School of Medicine, Morgantown, WV, United States.
James H BerryDepartment of Behavioral Medicine and Psychiatry, Rockefeller Neuroscience Institute, West Virginia University School of Medicine, Morgantown, WV, United States.
Steven D ShirkDepartment of Neuroscience, Rockefeller Neuroscience Institute, West Virginia University School of Medicine, Morgantown, WV, United States.
Manish RanjanDepartment of Neuroscience, Rockefeller Neuroscience Institute, West Virginia University School of Medicine, Morgantown, WV, United States.
Ali R RezaiDepartment of Neuroscience, Rockefeller Neuroscience Institute, West Virginia University School of Medicine, Morgantown, WV, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Identifying predictors of relapse/drug use recurrence (DUR) in real-time could allow the rapid implementation of overdose prevention interventions for those with substance use disorders (SUD). Wearable devices and phone-based applications for self-reported assessments in the patient's natural environment [e.g., ecological momentary assessment (EMA)] have potential for predicting DUR. Peer recovery support specialists (PRSS) play a critical role in reducing DUR risk. The benefits of utilizing PRSS resources in response to alerts derived from wearable technology and EMA data are unknown. This feasibility study investigates a) the use of wearable technologies/EMA to predict physiological/behavioral biomarkers of DUR and b) opportunities for PRSS-based interventions based on predictions. Methods: Participants were recruited from various settings (e.g., SUD treatment, sober living), were provided a commercial wearable device (Oura ring), and were prompted daily to complete an EMA application assessing mood and substance cravings. Participants were monitored for 90 days (Baseline Phase), then randomized to the Standard of Care (SoC) or PRSS Intervention arm and followed for two 90-day phases. When machine learning algorithms detected an anomaly, an alert was sent to the participant's phone. The PRSS was sent an alert to contact participants in the PRSS Intervention arm. Results: Of 229 participants enrolled, 108 provided EMA and Oura data for ≥1 of 90 days during Baseline, Phase 1, and Phase 2; 63 provided ≥30% of the data across the 3 phases. Twenty-six were randomized to the PRSS Intervention arm, and 37 were randomized to the SoC arm. The PRSS made 483 call attempts for unique alerts; the average per participant across the study was ∼20 (median = 15; range = 1-53). The PRSS intervention arm had modest but significant decreases in anxiety, stress, depression, angst composite (all Discussion: This feasibility study highlights the potential benefits and barriers for using models to predict risk factors for DUR via wearable devices and EMA and supports the utility of a PRSS intervention once the model detects an elevated risk for DUR. Patient compliance and attrition must be improved to optimize this approach as a clinical tool. We discuss challenges and recommend strategies for future studies.

Indexed as

drug use recurrenceecological momentary assessmentoverdosepeer recovery support specialistrelapsesubstance use disorderwearable technology

Identifiers

PMID42490870
PMCPMC13375731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.